Subscribe
Sign in
Share this post
The Drug Development Letter
After 23 years, imatinib remains the best front-line therapy in CML. Why use accelerated approval in a setting where patients have a life expectancy comparable to the general population?
Copy link
Facebook
Email
Notes
More
After 23 years, imatinib remains the best…
Timothée Olivier
Nov 4, 2024
16
Share this post
The Drug Development Letter
After 23 years, imatinib remains the best front-line therapy in CML. Why use accelerated approval in a setting where patients have a life expectancy comparable to the general population?
Copy link
Facebook
Email
Notes
More
1
1
Asciminib - a novel TKI - in Newly Diagnosed Chronic Myeloid Leukemia.
Read →
1 Comment
medstudent
Nov 4
Liked by Timothée Olivier
Great post. Thank you
Expand full comment
Reply
Share
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
Great post. Thank you